

Why are we reviewing the evidence on  
meningococcal A conjugate vaccine ?

What are the questions for SAGE ?

Professor Kate O'Brien, SAGE Member

Meningococcal A conjugate vaccine impact and routine immunization schedule in infants and young children  
Session 6 - Meeting of the Strategic Advisory Group of Experts on Immunization (SAGE)  
Geneva, 22 October 2014

# Background (1)



- **MenAfriVac (MenA-TT)**
  - 2009 licensed on immunogenicity
  - 2010 WHO Pre-qualified
  - Single IM dose
  - 1-29 years
- **A,C, Y, W135 Men Conjugate Vaccines also licensed**
  - 2005, 2010 & 2012
  - 1 dose: 1 yo or 2-55 yo
  - 2 doses: 9-23 months
- **A, C, Y, W135 Men Polysaccharides**



## Nov 2011 WHO position paper

- High/medium endemic & epidemic countries
- Low endemicity settings
- Risk groups
- Preference for Men-conjugates


# 2011 WHO Position Paper Recommendations

## High/Medium Endemic and Epidemic Countries




### Large Scale Vaccine Programs

- Africa Meningitis Belt
  - 1- 29 m target MenA Conjugate
- Plus
  - SIA every 3-5 years or
  - Incorporation into Routine Immunization
- Need for booster not yet established
- No statements on pregnancy, but...
  - GACVS statements 2010, 2014
  - WHO's technical guidance note endorsed by SAGE and GACVS, Dec. 2010




# 2011 WHO Position Paper Recommendations

## African Meningitis Belt and MenA Conjugate



- Niger, BF, Mali campaigns
- Complete efforts to control Men A in African meningitis belt
- High quality surveillance for impact
  - Disease
  - Carriage
- Apply MenA control program to strengthen
  - Routine EPI programme
  - Pharmacovigilance infrastructure

# MenA Conjugate Vaccine Progress 2011-2014



- 153 million people immunized
  - 1-29 year olds
  - MenAfriVac Campaigns in 12/26 countries
  - Benin, Burkina Faso, Cameroon, Chad, Ethiopia, The Gambia, Ghana, Mali, Niger, Nigeria, Senegal, Sudan
- Vaccine impact on invasive disease and carriage
- Completion of vaccine trials in infants < 1yo
- Study of MenA-CV in pregnancy
- Next Steps.....

# Questions for SAGE on Men A Vaccine

## For decision

1. What is (are) the preferred schedule(s) for meningococcal A conjugate vaccine.....
  - infants and young children
  - countries of the African meningitis belt
  - to achieve sustainable disease control following the initial mass vaccination campaigns?

### **Update of the meningococcal position paper**

2. What are priority gaps in policy-oriented information?

# Men A Vaccine Session Format

1. Progress on Men A Campaign Roll-Out
  - Mamoudou Djingarey, WHO
2. Clinical Trials in Infancy and Young Children; Safety in Pregnancy; Routine Coverage Data
  - Abraham Hodgson, Ghana
3. Modeling of Men A Future Strategies and Evidence Needs to Inform Policy
  - Caroline Trotter, University of Cambridge
4. Questions
5. Decision on Preferred Schedules for Infants and Young Children
  - Kate O'Brien, SAGE Member